Next Article in Journal
The Effect of Growth Medium Strength on Minimum Inhibitory Concentrations of Tannins and Tannin Extracts against E. coli
Next Article in Special Issue
Cinnamoyl Sucrose Esters as Alpha Glucosidase Inhibitors for the Treatment of Diabetes
Previous Article in Journal
Tannin-Rich Plants as Natural Manipulators of Rumen Fermentation in the Livestock Industry
Previous Article in Special Issue
Synthesis and Spectroscopic Analysis of Piperine- and Piperlongumine-Inspired Natural Product Scaffolds and Their Molecular Docking with IL-1β and NF-κB Proteins
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Hybrid Quinoline-Sulfonamide Complexes (M2+) Derivatives with Antimicrobial Activity

by
Dumitrela Diaconu
1,2,
Violeta Mangalagiu
2,*,
Dorina Amariucai-Mantu
1,
Vasilichia Antoci
1,
Cristian Levente Giuroiu
3,* and
Ionel I. Mangalagiu
1,2,*
1
Faculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol Bvd, 700506 Iasi, Romania
2
Institute of Interdisciplinary Research—CERNESIM Center, Alexandru Ioan Cuza University of Iasi, 11 Carol Bvd, 700506 Iasi, Romania
3
Endodontics, Faculty of Dental Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universităţii Street, 700115 Iasi, Romania
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(12), 2946; https://doi.org/10.3390/molecules25122946
Submission received: 14 May 2020 / Revised: 15 June 2020 / Accepted: 24 June 2020 / Published: 26 June 2020

Abstract

:
Two new series of hybrid quinoline-sulfonamide complexes (M2+: Zn2+, Cu2+, Co2+ and Cd2+) derivatives (QSC) were designed, synthesized and tested for their antimicrobial activity. The synthesis is straightforward and efficient, involving two steps: acylation of aminoquinoline followed by complexation with metal acetate (Cu2+, Co2+ and Cd2+) or chloride (Zn2+). The synthesized QSC compounds were characterized by FTIR and NMR spectroscopy and by X-ray diffraction on single crystal. The QSC compounds were preliminary screened for their antibacterial and antifungal activity and the obtained results are very promising. In this respect, the hybrid N-(quinolin-8-yl)-4-chloro-benzenesulfonamide cadmium (II), considered as leading structure for further studies, has an excellent antibacterial activity against Staphylococcus aureus ATCC25923 (with a diameters of inhibition zones of 21 mm and a minimum inhibitory concentration (MIC) of 19.04 × 10−5 mg/mL), a very good antibacterial activity against Escherichia coli ATCC25922 (with a diameters of inhibition zones of 19 mm and a MIC of 609 × 10−5 mg/mL), and again an excellent antifungal activity against Candida albicans ATCC10231 (with a diameters of inhibition zones of 25 mm and a MIC of 19.04 × 10−5 mg/mL).

Graphical Abstract

1. Introduction

Despite of the significant advances in the antimicrobial therapy accomplished in the last few decades, infectious diseases caused by microorganisms (bacteria, fungus, viruses, Mycobacterium tuberculosis, etc.) represent seriously threaten of modern medicine and global public health. Drug resistance, multi-drug resistance and extensively-drug-resistance are the leading cause of these drawbacks, but some other causes could be also taken into consideration [1,2,3]. Quinoline based compounds are small molecules of huge importance from pharmacological point of view, having a wide range of biological activities such as antiplasmodial and antimalarial, antibacterial, antifungal, antitubercular, anti-HIV, antiviral (including against COVID-19), etc. [4,5,6,7,8,9,10,11,12,13,14,15,16]. A special class of quinoline derivatives which pay a particularly attention on scientific community, are quinoline-sulfonamide complexes (QSC), studied especially for their fotoluminiscent (mostly fluorescent) properties [17,18,19,20,21,22,23]. As far for biological activity, these compounds were tested mostly as antiprotozoals [24,25] and very few data was found for their antibacterial and antifungal activity [26]. The antibacterial activity of azaheterocycles sulfonamides is well known [1,2].
Encouraged by our recent results in the field of (di)azine with antimicrobial activity [11,15,27,28,29,30,31,32,33,34,35,36,37,38,39,40], we report here the design, synthesis, antibacterial and antifungal evaluation of some newly hybrid quinoline-sulfonamide complexes.

2. Results and Discussion

2.1. Design and Chemistry

Having in view the biological potential of quinoline and sulfonamide scaffolds (especially antimicrobial) [9,10,11,12,13,14,15], as well as those one of quinoline-sulfonamide combined scaffold (especially anti-HIV-1) [16], we decide to combine the pharmacophoric properties of these core scaffolds with the complementary biological properties of counter cation M2+ (M2+: Zn2+, Cu2+, Co2+ and Cd2+), with the final goal of obtaining better biological activity and better pharmacokinetic properties for our compounds. In this respect, we design two new classes of hybrid quinoline-sulfonamide complexes, namely N-(quinolin-8-yl)-4-R-benzene sulfonamide metal (II) (QBSC) and N-(quinolin-8-yl)-quinoline -8-sulfonamide metal (II) (QQSC), Scheme 1.
As in related cases [21,22,23,24], the general route to obtain the desired compounds involves a simple and efficient two-step procedure. The first step consist in the acylation of (3, 4 or 8)amino-quinoline with variously 4-R-benzenesulfonyl chlorides (R = Cl, NO2, OMe) and quinolylsulfonyl chlorides, when the corresponding ligands quinoline-sulfonamide type 3 are obtained. The second step consist in the complexation of ligands 3 with metal acetate (Cu2+, Co2+, Cd2+) or chloride (Zn2+). In this way, we obtained the two classes of compounds desired: QBSC type 46 and QQSC type 7. The procedure is depicted in Scheme 2 for the complexes derived from 8-aminoquinoline.
The structures of QSC compounds were proved by elemental and spectral analysis (FT-IR, 1H-NMR, 13C{1H}-NMR, and two-dimensional experiments 2D-COSY, HMQC, HMBC), and single crystal X-ray structure determination. If we consider the M2+[N-(quinolin-8-yl)-4-chloro-benzenesulfonamide]2 derivatives QBSC 4ad as representative for the hybrid QSC, the spectral analysis reveal strong evidence for the proposed structures.
In the FT-IR spectra of sulfonamide ligand 3a and its complexes QBSC 4ad (Figure 1), the most representative bands, together with their assignments, are given in Table 1.
The band from 3267 cm−1 (medium intensity), which is corresponding to the N–H stretching vibration in the free ligand, is missing in the spectra of the complexes, confirming deprotonation of the nitrogen atom of the sulfonamide and its coordination to the metal ion. The bands corresponding to the asymmetric and symmetric stretching vibration of the sulfonyl group in ligand appear at 1372 cm−1 respectively at 1177 cm−1, while in spectra of the complexes are shifted with ≈20 cm−1 to higher wave numbers respectively ≈40 cm−1 to lower wave numbers; this is because in the free ligand a larger double bond character of the SO bonds could be incriminated. The band due to the sulfonyl group is split in the spectra of the complexes, because of the different spatial orientation of these groups, as the X-ray show. We also notice a similar shift with ≈20 cm−1 to higher wave numbers for the S–N stretching vibration in the spectra of the complexes, probably because the N atom is involved in the bonding to the metal atom. The remaining bands appear at wave numbers in accordance with the proposed structures both in the free ligand and complexes.
The 1H-NMR and 13C{1H}-NMR spectra of the sulfonamide ligand and its complexes shows characteristic chemical shifts that are in agreement to the proposed structure. The most significant signal in the 1H-NMR spectra (Figure 2), corresponding of the hydrogen atom from sulfonamide group H9 and, appear in the free ligand at a chemical shift of 10.20 ppm. This signal is missing in the spectra of QBSC complexes, which is a solid prove for the complexation with the metal ion. We could also notice that the signals of hydrogen atoms near the metal ion H2, H3, H4 (from pyridine ring), are deshielded in QBSC complexes with about 0.30 ppm due to the powerful deshielding effect of the metal ion, a electron density transfer from the ligand to the metal ion being responsible for this.
Similar considerations could be done for 13C{1H}-NMR spectra, Figure 3. The most relevant signals in the 13C{1H}-NMR spectra, correspond to the carbon atoms C2′, C8, C5 and C7. In QBSC complexes, the C2′ carbons (ipso-sulfonamide) appear to a chemical shift of about 142 ppm due to the powerful deshielding effect of sulfonamide group and the metal ion, while C8 (carbon from attached benzene ring of quinoline) appear to a chemical shift of about 141 ppm, the same reasons being incriminated. Comparative with the free ligand, in QBSC complexes, these carbons are deshielded with about 8 ppm for C8, respectively, with about 4 ppm for C2′, due to the powerful deshielding effect of the metal ion. The most shielded carbons are C5 and C7. In QBSC complexes, these carbons appear to a chemical shift of about 117 ppm for C5, respectively, 115 ppm for C7, being shielded comparative with the free ligand with about 20 ppm for C5 respectively with about 2 ppm for C7. As far for the NMR spectra of Cu2+ and Co2+ complexes, the spectra are broad because of their different magnetic properties (paramagnetic).
In the case of compounds 4b and 4c, the structure of compounds was assigned unambiguously by single-crystal X-ray investigation (for 4a and 4d, we did not obtained yet proper crystals), Figure 4A,B.
The structure of QBSC cobalt complex 4c was resolved by direct methods and refined in the monoclinic P21/n space group type. Molecular information’s shows a tetrahedral coordination of cobalt with the bidentate ligand trough Co-Nquinoline and Co-Nsulfonamide bonds. The Co-Nquinoline bond lengths (2.038 and 2.029 Å) are slightly larger than Co-Nsulfonamide bonds (1.970 and 1.983 Å) but in an acceptable range as reported by other papers for similar complexes. The structure of QBSC copper complex 4b was resolved by direct methods and refined in the monoclinic I2/a space group type. Molecular information’s shows a tetrahedral coordination of copper with the bidentate ligand trough Cu-Nquinoline and Cu-Nsulfonamide bonds. The Cu-Nquinoline bond lengths (1.980 and 1.991 Å) are slightly larger than Cu-Nsulfonamide bonds (1.960 and 1.944 Å) but in an acceptable range as reported by other papers for similar complexes. Copies of NMR spectra of ligand and QBSC complexes and checkCIF files for X-ray data of QBSC complex 4b and 4c are presented to Supplementary Materials.

2.2. Antimicrobial Assay

The in vitro antimicrobial activity of ligand 3 and QSC compounds 4ad was determined by the Kirby–Bauer disk diffusion method [41] using nutrient agar medium (Mueller Hinton agar for antibacterial tests and Sabouraud agar for antifungal tests). The antibacterial activity was evaluated against two strains bacteria (Gram-positive Staphylococcus aureus ATCC 25923 and Gram-negative Escherichia coli ATCC 25922) and the antifungal activity against fungus Candida albicans ATCC 10231. As positive control (C+) was used, Penicillin 10 IU for Staphylococcus aureus, Carbenicillin 100 µg/mL for Escherichia coli and Nystatin 500,000 IU for Candida albicans; the negative control (C−) consist in sterile filter paper disks with no antimicrobial compounds. The more susceptible were the germs, the larger the diameter (mm) of the inhibition zones is. The obtained results are expressed as diameters of inhibition zones (mm) and, for ligand 3, and QBSC 4ad compounds, are presented in Table 2 and Figure 5A–C.
From the data presented in Table 2 and Figure 5A–C, we may notice that some of our QBSC compounds demonstrated to be effective against the tested strain. Against bacterial strain Staphylococcus aureus one compound QBSC 4d is very active (having a diameter of inhibition zone of 21 mm) and three others compounds are active: QBSC 4c, QBSC 4b and the ligand 3a (with the diameter of inhibition zone of 17, 16 and 18 mm). Against bacteria Escherichia coli one compound QBSC 4d is active (19 mm) while against fungus Candida albicans two compounds are very active: QBSC 4d and the ligand 3a (25 respectively 26.5 mm).
The compounds which exhibited significant antimicrobial activity were later tested using the standardized broth microdilution assay procedure to determine the minimum inhibitory concentration (MIC) of the compounds under investigation against the reference microorganisms [42]. The resulted MIC value is defined as the lowest concentration of the antimicrobial agent under investigation, which prevents visible growth of the tested microorganism. The obtained results are listed in Table 3.
As we may notice from Table 3, Cd complex (QBSC 4d) is active to a very low concentration, having a MIC of 19.04 × 10−5 mg/mL in the case of Staphylococcus aureus and Candida albicans, respectively 609 × 10−5 mg/mL in the case of Escherichia coli. Significant results was obtained also for Cu complex (QBSC 4b) which have MIC value of 4875 × 10−5 mg/mL in the case of bacterial streams Staphylococcus aureus and Escherichia coli.
The diameter of inhibition zone and MIC data reveal that our QBSC compounds (except the Zn complexes) have a quasi-nonselective activity against bacteria Staphylococcus aureus. Against Escherichia coli only Cd complex (QBSC 4d) have a significant activity, while against fungus Candida albicans Cd complex (QBSC 4d) and quinoline sulfonamide ligand (3a) present a strong activity. The above presented results also reveal a clear influence of the metal cation, the Cd complex (QBSC 4d) being far away the most active tested compound, having a quasi-nonselective antibacterial and antifungal activity. The activity of cadmium complexes are higher the most probable because of a better synergism ligand cadmium.
As to the mechanism of action of our QBSC compounds, we may presume that they could act as carbonic anhydrase inhibitors, as the literature describe for related compounds [26,43].

3. Experimental

3.1. Chemistry

All the reagents and solvents were purchased from commercial sources and used without further purification. Melting points were recorded on a Electrothermal MEL-TEMP II (Barnstead International, Dubuque, IA, USA) apparatus in open capillary tubes and are uncorrected. Analytical thin-layer chromatography (TLC) was performed with commercial Merck silica gel 60 F254 plates and visualized with UV light (λmax = 254 or 365 nm). The NMR spectra were recorded on a Bruker Avance III 500 MHz spectrometer (Bruker Vienna, Austria) operating at 500 MHz for 1H and 125 MHz for 13C. Chemical shifts were reported in delta (δ) units, part per million (ppm) and coupling constants (J) in Hz. The following abbreviations were used to designate chemical shift multiplicities: s = singlet, d = doublet, ad = apparent doublet, t = triplet, q = quartet, aq = apparent quartet, m = multiplet. Infrared (IR) data were recorded as films on potassium bromide (KBr) pellets on a FT-IR VERTEX 70 Bruker spectrophotometer. In order to determine the structure of complexes, a crystal of each complex was selected, mounted on a hair thread and inserted into the four-circle SuperNova single crystal diffraction instrument. Data acquisition was made at 100 °K (−173.15 °C) using CuKa radiation. A number of 5608 reflections from a total of 33212 acquired in 2.8345 < θ < 70.8363 range were used for refinement and structure solution.
Compound 3a, which have already been reported in literature, showed spectral data in agreement to the reported data [16,17,20].

3.1.1. General Procedure for the Synthesis of Sulfonamide Ligand 3a and its Complexes 4ad

Synthesis of the Ligand

4-chloro-N-(quinolin-8-yl)benzenesulfonamide (3a), 1 mmol of 8-aminoquinoline was dissolved in minimum volume of dichloromethane CH2Cl2, then was added to a stirred solution of 4-chlorobenzenesulfonyl chloride (1.1 mmol) and pyridine. The crude product was washed with HCl (1 M), then with a solution of saturated NaHCO3. The organic extract was dried on Na2SO4 and the solvent was removed in vacuum. The solid obtained was purified on column chromatography (CH2Cl2/AcOEt = 70/30) giving the white solid 4-chloro-N-(quinolin-8-yl)benzenesulfonamide.

Synthesis of the Complexes

The complexes were prepared by direct reaction between the sulfonamide ligand and Zn(II), Cu(II), Co(II) and Cd(II) salts.
[Zn(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] (4a), 2 mmol of sulfonamide ligand 3a were dissolved in 70 mL MeOH and 2 mL NH4OH were added. 1 mmol of ZnCl2 dissolved in 50 mL methanol were added dropwise while solution was magnetically stirred. When addition is completed, a yellow precipitate is formed, which is separated by filtration. Addition of a base for deprotonating the nitrogen from amine was necessary to prepare the zinc complex. [21]
[Cu(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2],[Co(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2], [Cd(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] (4bd), on a methanolic solution of metal (Cu, Co and Cd) (II) acetate (1 mmol) was added dropwise 80 mL of a solution containing 2 mmol of sulfonamide-ligand 3a. After overnight stirring at room temperature, crystals were formed and they were separated by filtration [23].
4-chloro-N-(quinolin-8-yl)benzenesulfonamide (3a), White solid; yield: 87%; mp 129–130 °C; IR (KBr), νmax 3267, 1584, 1506, 1372, 1177, 1094, 927, 755, 624, 562 cm−1; 1H NMR (500 MHz, DMSO-d6) δ 7.54 (4H, m, 2 × H-4′, H-6, H-3), 7.68 (2H, m, H-7, H-5), 7.89 (2H, d, J = 8.5 Hz, 2 × H-3′), 8.35 (1H, dd, J = 8.5 Hz, J = 1.5 Hz, H-4), 8.84 (1H, dd, J = 4.5 Hz, J = 1.5 Hz, H-2), 10.20 (1H, s, H-9); 13C{1H} NMR (125 MHz, DMSO-d6) δ 117.79 (C-7), 122.33 (C-3), 123.57 (C-5), 126.66 (C-6), 128.17 (C-4a), 128.88 (2 × C-3′), 129.23 (2 × C-4′), 133.38 (C-8), 136.52 (C-4), 137.91 (C-5′), 138.47 (C-2′), 139.14 (C-8a), 149.45 (C-2); Anal. Calcd. for C15H11ClN2O2S C, 56.52; H, 3.48; N, 8.79. Found C, 56.47; H, 3.51; N, 8.74.
[Zn(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] (4a), Yellowish green crystals; yield 92%; IR (KBr), νmax 3390, 1583, 1507, 1471, 1389, 1196, 1138, 954, 753, 624, 572 cm−1; 1H NMR (500 MHz, DMSO-d6) δ 7.30 (2H, dd, J = 6.0 Hz, J = 2.5 Hz, 2 × H-7), 7.43 (4H, ad, J = 6.0 Hz, 2 × H-6, 2 × H-5), 7.52 (4H, d, J = 8.5 Hz, 4 × H-4′), 7.78 (2H, aq, J = 6.5 Hz, 2 × H-3), 8.00 (4H, d, J = 8.5 Hz, 4 × H-3′), 8.59 (2H, d, J = 7.5 Hz, 2 × H-4), 9.23 (2H, ad, J = 3.0 Hz, 2 × H-2); 13C{1H} NMR (125 MHz, DMSO-d6) δ 115.07 (2 × C-7), 117.52 (2 × C-5), 122.38 (2 × C-3), 128.38 (2 × C-6), 128.94 (2 × C-4a), 129.01 (4 × C-3′), 129.07 (4 × C-4′), 136.32 (2 × C-5′), 138.30 (2 × C-8a), 140.55 (2 × C-8), 140.70 (2 × C-4), 141.26 (2 × C-2′), 148.65 (2 × C-2); Anal. Calcd. for C30H20Cl2N4O4S2Zn C, 51.41; H, 2.88; N, 7.99. Found C, 51.47; H, 2.81, N 8.04.
[Cu(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] (4b), Dark brown crystals; yield 85%; IR (KBr), νmax 1583, 1507, 1467, 1385, 1155, 954, 753, 624, 572 cm−1; Anal. Calcd. for C30H20Cl2CuN4O4S2 C, 51.54; H, 2.88; N, 8.01. Found C, 51.59; H, 2.80, N 8.06.
[Co(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] (4c), Brick-red crystals; yield 87%; IR (KBr), νmax 1584, 1502, 1468, 1386, 1195, 1151, 961, 755, 624, 572 cm−1; Anal. Calcd. for C30H20Cl2CoN4O4S2 C, 51.89; H, 2.90; N, 8.07. Found C, 51.94; H, 2.86, N 8.11.
[Cd(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] (4d), Beige crystals; yield 79%; IR (KBr), νmax 1578, 1503, 1468, 1323, 1275, 1136, 957, 859, 753, 621, 568 cm−1; 1H NMR (500 MHz, DMSO-d6) δ 7.30 (6H, m, 2 × H-7, 2 × H-6, 2 × H-5), 7.38 (4H, d, J = 8.5 Hz, 4 × H-4′), 7.78 (2H, aq, J = 8.0 Hz, 2 × H-3), 8.00 (4H, d, J = 8.0 Hz, 4 × H-3′), 8.40 (2H, d, J = 8.0 Hz, 2 × H-4), 9.15 (2H, ad, J = 4.5 Hz, 2 × H-2); 13C{1H} NMR, (125 MHz, DMSO-d6) δ 114.53(2 × C-7), 116.63 (2 × C-5), 121.61 (2 × C-3), 127.51 (2 × C-6), 128.24 (4 × C-3′), 129.04 (2 × C-4a), 129.38 (4 × C-4′), 135.57 (2 × C-5′), 138.46 (2 × C-8a, 2 × C-4), 141.43 (2 × C-8), 142.48 (2 × C-2′), 148.50 (2 × C-2); Anal. Calcd. for C30H20CdCl2N4O4S2 C, 48.18; H, 2.70; N, 7.49. Found C, 48.10; H, 2.78, N 7.42.

3.2. Antimicrobial Assay

3.2.1. Disk-Diffusion Method

For inoculum preparation, reference microbial cultures of bacteria (Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922) and fungi (Candida albicans ATCC 10231) were employed. A number of approximately 5 colonies from each type of culture were used to inoculate 10 mL of Mueller Hinton (MH) agar (for antibacterial tests) and Sabouraud agar (for antifungal tests). Using a Beckman Coulter DU 730 spectrophotometer (λ = 600 nm), the turbidity of the inoculum was adjusted to a 0.5 McFarland standard (1–2 × 108 CFU/mL for bacteria and 1–5 × 106 CFU/mL for Candida), and the inoculum was transferred, in a 1 mL volume, onto the surface of the growth media specific for bacteria (MH) and fungi (Sabouraud). Once the inoculum was absorbed, sterile paper disks of approximately 6 mm in diameter and impregnated with 10 µL of antibacterial compound (dissolved in DMSO 3%) were placed on the surface of the culture media; for all the tested compounds, the concentration used was 25 mg/mL. Following incubation at the optimal temperatures for bacteria and fungi, of 37 °C and 28 °C, respectively, for 24 h (bacteria) and 72 h (fungi), the diameters of the inhibition zones were measured using a ruler. The controls were prepared in the same growth conditions (i.e., C+: sterile filter paper disks impregnated with antibiotics inducing sensitivity in the organisms under investigation, namely Penicillin 10 IU for Staphylococcus aureus, Carbenicillin 100 µg/mL for Escherichia coli and Nystatin 500,000 IU for Candida albicans, and C−: sterile filter paper disks with no antimicrobial compounds).

3.2.2. Broth Microdilution Method

The working technique involves the use of a 96-well microtiter plate (microdilution). In each well of the plate, 80 µL of growth medium MH, 10 µL of microbial inoculum (Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, or Candida albicans ATCC 10231) prepared in the same manner as in the diffusion test (i.e., by diluting the standardized microbial suspension adjusted to a 0.5 McFarland standard), and 100 µL of antimicrobial substance to be tested were transferred by pipetting, in different concentrations. To this purpose, double dilutions of the antimicrobial agent were made in the DMSO 3%, starting with the 25 mg/mL dilution (e.g., 12.5 mg/mL, 6.25 mg/mL, 3.12 mg/mL, 1.56 mg/mL, 0.78 mg/mL and so on). For each tested microorganism, a positive control C+ (containing 80 µL of MH growth medium and 10 µL of antimicrobial compound) and a negative one C- (containing 80 µL of MH growth medium and 10 µL of diluted microbial culture) were prepared. Following the incubation of the microplates at 37 °C for 24 h (for Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922) and at 28 °C for 72 h (for Candida albicans ATCC 10231), 10 µL of resazurin were added in each well. The samples were incubated once again at the temperature optimal for each microorganism for one hour. The color of the indicator turned from purple to pink. Resazurin is a colorimetric indicator for cell viability widely applied for monitoring cell proliferation. The redox dye, resazurin, enters the cytosol in the oxidized form (purple–blue) and is converted to the reduced form, resorufin (pink).

4. Conclusions

Two new series of hybrid quinoline-sulfonamide complexes (M2+: Zn2+, Cu2+, Co2+ and Cd2+) derivatives were designed, synthesized and tested for their antimicrobial activity. The synthesis is straight and efficient, involving two steps: acylation of aminoquinoline followed by complexation with metal acetate (Cu2+, Co2+ and Cd2+) or chloride (Zn2+). The synthesized compounds were characterized by FTIR, NMR spectroscopy and by X-ray diffraction on single crystal. The Co (II) complex crystallize in the monoclinic P21/n space group type, with a tetrahedral coordination of cobalt with the bidentate ligand trough Co-Nquinoline and Co-Nsulfonamide bonds. The QSC compounds were preliminary in vitro screened for their antibacterial and antifungal activity and the obtained results are very promising. Against bacterial strain Staphylococcus aureus one compound have an excellent antibacterial activity QBSC 4d (Φ = 21 mm, MIC = 19.04 × 10−5 mg/mL) and three others compounds are active: QBSC 4c, QBSC 4b and the quinoline sulfonamide ligand 3a (Φ of 17, 16 and 18 mm). Against bacteria Escherichia coli only one compound QBSC 4d present activity (19 mm, MIC of 609 × 10−5 mg/mL). Against fungus Candida albicans again the QBSC 4d complex have an excellent antibacterial activity (Φ = 25 mm, MIC = 9.04 × 10−5 mg/mL) and also the ligand 3a have an excellent antibacterial activity (Φ = 26.5 mm) but to a relatively high concentration (MIC = 12.5 mg/mL). These results reveal a clear influence of the metal cation, the Cd complex (QBSC 4d) being far away the most active tested compound, having a quasi-nonselective antibacterial and antifungal activity. The activity of cadmium complexes are higher the most probable because of a better synergism ligand cadmium.

Supplementary Materials

The following are available online: 1H- and 13C-NMR of compounds 3a, 4a, 4d (pages 1–4), chechCIF reports for compounds 4b and 4c (pages 5–11).

Author Contributions

Design, conception and writing: V.M. and I.I.M.; Synthesis, structure elucidation and biological data analysis: D.D., V.M., D.A.-M., V.A., C.L.G. and I.I.M. All authors also reviewed and approved the final version. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

Authors are thankful to CERNESIM, for NMR and X-ray experiments. The authors gratefully acknowledge Simona Dunca for her help in biological assay and senior researcher Tiberiu Roman in X-ray experiments.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Brunton, L.; Knollmann, B.; Hilal-Dandan, R. Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 13th ed.; McGraw-Hill: New York, NY, USA, 2013; ISBN 9781259584732. [Google Scholar]
  2. Silverman, R.B.; Holladay, M.W. The Organic Chemistry of Drug Design and Drug Action, 3rd ed.; Academic Press: Cambridge, MA, USA, 2014; ISBN 9780123820303. [Google Scholar]
  3. WHO Global Strategy for Containment of Antimicrobial Resistance. Available online: https://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf (accessed on 14 June 2020).
  4. Guarner, J. Three Emerging Coronaviruses in Two Decades the Story of SARS, MERS, and Now COVID-19. Am. J. Clin. Pathol. 2020, 153, 420–421. [Google Scholar] [CrossRef] [PubMed]
  5. Xiao, C.; Li, X.; Liu, S.; Gao, S.J.; Gao, F. HIV-1 did not contribute to the 2019-nCoV genome. Emerg. Infect. Dis. 2020, 9, 378–381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Kandeel, M.; Al-Nazawi, M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci. 2020, 251, 117627. [Google Scholar] [CrossRef] [PubMed]
  7. Vellingiri, B.; Jayaramayya, K.; Iyer, M.; Kumar, N.S.; Subramaniam, M.D. COVID-19: A promising cure for the global panic. Sci. Total Environ. 2020, 725, 138277. [Google Scholar] [CrossRef] [PubMed]
  8. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020, 367, 1444–1448. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Kumari, L.S.; Mazumder, A.; Kumar, V.; Gupta, S. Synthesis and biological potentials of quinoline analogues: A review of literature. Mini-Rev. Org. Chem. 2019, 16, 653–688. [Google Scholar] [CrossRef]
  10. Zhang, J.; Wang, S.; Ba, Y.; Xu, Z. 1,2,4-Triazole-quinoline/quinolone hybrids as potential anti-bacterial agents. Eur. J. Med. Chem. 2019, 174, 1–8. [Google Scholar] [CrossRef]
  11. Al Matarneh, C.; Sardaru, M.; Apostu, M.; Rosca, I.; Ciobanu, C.; Mangalagiu, I.I.; Danac, R. Synthesis and antibacterial evaluation of new pyrrolo[3’,4′:3,4]pyrrolo[1,2-a]quinoline and pyrrolo[3′,4′:3,4]pyrrolo[1,2-a]isoquinoline derivatives. Studia UBB Chem. 2019, 64, 67–80. [Google Scholar] [CrossRef]
  12. Kalaria, P.N.; Karad, S.C.; Raval, D.K. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. Eur. J. Med. Chem. 2018, 158, 917–936. [Google Scholar] [CrossRef]
  13. Ajani, O.O.; Iyaye, K.T.; Audu, O.Y.; Kuye, A.O.; Olanrewaju, I.O. Microwave Assisted Synthesis and Antimicrobial Potential of Quinoline-Based 4-Hydrazide-Hydrazone Derivatives. J. Heterocycl. Chem. 2018, 55, 302–312. [Google Scholar] [CrossRef] [Green Version]
  14. Hu, Y.Q.; Gao, C.; Zhang, S.; Xu, L.; Xu, Z.; Feng, L.S.; Wu, X.; Zhao, F. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem. 2017, 139, 22–47. [Google Scholar] [CrossRef]
  15. Mantu, D.; Antoci, V.; Moldoveanu, C.; Zbancioc, G.; Mangalagiu, I.I. Hybrid imidazole (benzimidazole)/pyridine (quinoline) derivatives and evaluation of their anticancer and antimycobacterial activity. J. Enz. Inhib. Med. Chem. 2016, 31, 96–103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Zhong, F.; Geng, G.; Chen, B.; Pan, T.; Li, Q.; Zhang, H.; Bai, C. Identification of benzenesulfonamide quinoline derivatives as potent HIV-1 replication inhibitors targeting Rev protein. Org. Biomol. Chem. 2015, 13, 1792–1799. [Google Scholar] [CrossRef] [PubMed]
  17. Sen, C.; Sahoo, T.; Singh, H.; Suresh, E.; Ghosh, S.C. Visible light-promoted photocatalytic C-5 carboxylation of 8-aminoquinoline amides and sulfonamides via a single electron transfer pathway. J. Org. Chem. 2019, 84, 9869–9896. [Google Scholar] [CrossRef] [PubMed]
  18. Pascual-Álvarez, A.; Topala, T.; Estevan, F.; Sanz, F.; Alzuet-Piña, G. Photoinduced and self-activated nuclease activity of copper(II) complexes with N-(quinolin-8-yl)quinolin-8-sulfonamide-DNA and bovine serum albumin binding. Eur. J. Inorg. Chem. 2016, 2016, 982–994. [Google Scholar] [CrossRef]
  19. Meeusen, J.W.; Tomasiewicz, H.; Nowakowski, A.; Petering, D.H. TSQ (6-methoxy-8-p-toluenesulfonamido-quinoline), a common fluorescent sensor for cellular zinc, images zinc proteins. Inorg. Chem. 2011, 50, 7563–7573. [Google Scholar] [CrossRef] [Green Version]
  20. Rouffet, M.; De Oliveira, C.A.F.; Udi, Y.; Agrawal, A.; Sagi, I.; McCammon, J.A.; Cohen, S.M. From sensors to silencers: Quinoline- and benzimidazole-sulfonamides as inhibitors for zinc proteases. J. Am. Chem. Soc. 2010, 132, 8232–8233. [Google Scholar] [CrossRef]
  21. Macías, B.; García, I.; Villa, M.V.; Borrás, J.; Castineiras, A.; Sanz, F. Synthesis and structural characterization of zinc complexes with sulfonamide containing 8-aminoquinoline. Z. Anorg. Allg. Chem. 2003, 629, 255–260. [Google Scholar] [CrossRef]
  22. Fahrni, C.J.; O’Halloran, T.V. Aqueous coordination chemistry of quinoline-based fluorescence probes for the biological chemistry of zinc. J. Am. Chem. Soc. 1999, 121, 11448–11458. [Google Scholar] [CrossRef]
  23. Da Silva, L.E.; de Sousa, P.T., Jr.; Joussef, A.C.; Piovezan, C.; Neves, A. Synthesis, structure and physicochemical properties of zinc and copper complexes based on sulfonamides containing 8-aminoquinoline ligands. Quim. Nova 2008, 31, 1161–1164. [Google Scholar] [CrossRef]
  24. Da Silva, L.E.; Joussef, A.C.; Pacheco, L.K.; Da Silva, D.G.; Steindel, M.; Rebelo, R.A.; Schmidt, B. Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl arylsulfonamides. Bioorg. Med. Chem. 2007, 15, 7553–7560. [Google Scholar] [CrossRef]
  25. Da Silva, L.E.; de Sousa, P.T., Jr.; Maciel, E.N.; Numes, R.K.; Eger, I.; Steindel, M.; Rebelo, R.A. In vitro antiprotozoal evaluation of zinc and copper complexes based on sulfonamides containing 8-aminoquinoline ligands. Lett. Drug Des. Discov. 2010, 7, 679–685. [Google Scholar] [CrossRef]
  26. Diaz, J.R.A.; Baldo, M.F.; Echeverría, G.; Baldoni, H.; Vullo, D.; Soria, D.B.; Supuran, C.T.; Cami, G.E. A substituted sulfonamide and its Co (II), Cu (II), and Zn (II) complexes as potential antifungal agents. J. Enz. Inhib. Med. Chem. 2016, 31, 51–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Antoci, V.; Cucu, D.; Zbancioc, G.; Moldoveanu, C.; Mangalagiu, V.; Amariucai-Mantu, D.; Aricu, D.; Mangalagiu, I.I. Bis-(imidazole/benzimidazole)-pyridine derivatives: Synthesis, structure and antimycobacterial activity. Future Med. Chem. 2020, 12, 207–222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Olaru, A.M.; Vasilache, V.; Danac, R.; Mangalagiu, I.I. Antimycobacterial activity of nitrogen heterocycles derivatives: 7-(pyridine-4-yl)-indolizine derivatives. Part VII. J. Enz. Inhib. Med. Chem. 2017, 32, 1291–1298. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Mantu, D.; Antoci, V.; Nicolescu, A.; Delenu, C.; Vasilache, V.; Mangalagiu, I.I. Synthesis, stereochemical studies and antimycobacterial activity of new acetyl-hydrazines pyridazinone. Curr. Org. Synth. 2017, 14, 112–119. [Google Scholar] [CrossRef] [Green Version]
  30. Al Matarneh, C.M.; Shova, S.; Mangalagiu, I.I.; Danac, R. Synthesis, structure, antimycobacterial and anticancer evaluation of new pyrrolo-(phenanthroline) derivatives. J. Enz. Inhib. Med. Chem. 2016, 31, 470–480. [Google Scholar] [CrossRef] [Green Version]
  31. Aricu, A.; Ciocarlan, A.; Lungu, L.; Barba, A.; Shova, S.; Zbancioc, G.; Mangalagiu, I.I.; D’Ambrosio, M.; Vornicu, N. Synthesis of new antibacterial and antifungal drimane sesquiterpenoids with azaheterocyclic units. Med. Chem. Res. 2016, 25, 2316–2323. [Google Scholar] [CrossRef]
  32. Al Matarneh, C.; Ciobanu, C.I.; Mangalagiu, I.I.; Danac, R. Design, synthesis and antimycobacterial activity of some new azaheterocycles: 4,7-phenanthroline with p-halogeno-benzoyl skeleton. Part VI. J. Serb. Chem. Soc. 2016, 81, 133–140. [Google Scholar]
  33. Danac, R.; Al Matarneh, C.M.; Shova, S.; Daniloaia, T.; Balan, M.; Mangalagiu, I.I. New indolizines with phenanthroline skeleton: Synthesis, structure, antimycobacterial and anticancer evaluation. Bioorg. Med. Chem. 2015, 23, 2318–2327. [Google Scholar] [CrossRef]
  34. Danac, R.; Daniloaia, T.; Antoci, V.; Vasilache, V.; Mangalagiu, I.I. Design, synthesis and antimycobacterial activity of some new azaheterocycles: Phenanthroline with p-halo-benzoyl skeleton. Part, V. Lett. Drug Des. Discov. 2015, 12, 14–19. [Google Scholar] [CrossRef]
  35. Balan, A.M.; Miron, A.; Tuchilus, C.; Rotinberg, P.; Mihai, C.T.; Mangalagiu, I.I.; Zbancioc, G. Synthesis and in vitro analysis of novel dihydroxyacetophenone derivatives with antimicrobial and antitumor activities. Med. Chem. 2014, 10, 476–483. [Google Scholar]
  36. Kuchkova, K.; Aricu, A.; Barba, A.; Vlad, P.; Shova, S.; Secara, E.; Ungur, N.; Tuchilus, C.; Zbancioc, G.; Mangalagiu, I.I. Design, syntheses and antimicrobial activity of some novel homodrimane sesquiterpenoids with diazine skeleton. Med. Chem. Res. 2014, 23, 1559–1568. [Google Scholar] [CrossRef]
  37. Tucaliuc, R.; Cotea, V.; Niculaua, M.; Tuchilus, C.; Mantu, D.; Mangalagiu, I.I. New pyridazine–fluorine derivatives: Synthesis, chemistry and biological activity. Part II. Eur. J. Med. Chem. 2013, 67, 367–372. [Google Scholar] [CrossRef] [PubMed]
  38. Mantu, D.; Antoci, V.; Mangalagiu, I.I. Design, synthesis and antituberculosis activity of some new pyridazine derivatives: Bis-pyridazine. Part IV. Infect. Disord. Drug Targets 2013, 13, 344–351. [Google Scholar] [CrossRef] [PubMed]
  39. Mantu, D.; Luca, M.C.; Moldoveanu, C.; Zbancioc, G.; Mangalagiu, I.I. Synthesis and antituberculosis activity of some new pyridazine derivatives. Part II. Eur. J. Med. Chem. 2010, 45, 5164–5168. [Google Scholar] [CrossRef]
  40. Balan, A.M.; Florea, O.; Moldoveanu, C.; Zbancioc, G.; Iurea, D.; Mangalagiu, I.I. Diazinium salts with dihydroxyacetophenone skeleton: Syntheses and antimicrobial activity. Eur. J. Med. Chem. 2009, 44, 2275–2279. [Google Scholar] [CrossRef]
  41. CLSI Document M07-A11. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 11th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018; Available online: https://clsi.org/media/1928/m07ed11_sample.pdf (accessed on 14 June 2020).
  42. Kavanagh, A.; Ramu, S.; Gong, Y.; Copper, M.A.; Blaskovich, M.A.T. Effects of microplate type and broth additives on microdilution MIC susceptibility assays. Antimicrob. Agents Ch. 2019, 63, 1–17. [Google Scholar] [CrossRef] [Green Version]
  43. Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008, 7, 168–181. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds are available from the authors.
Scheme 1. Design in the class of hybrid quinoline-sulfonamide complexes derivatives.
Scheme 1. Design in the class of hybrid quinoline-sulfonamide complexes derivatives.
Molecules 25 02946 sch001
Scheme 2. Reaction pathways to obtain hybrid quinoline-sulfonamide complexes derivatives.
Scheme 2. Reaction pathways to obtain hybrid quinoline-sulfonamide complexes derivatives.
Molecules 25 02946 sch002
Figure 1. FT-IR spectra of sulfonamide ligand 3a, zinc (II) complex (4a), copper (II) complex (4b), cobalt (II) complex (4c) and cadmium (II) complex (4d).
Figure 1. FT-IR spectra of sulfonamide ligand 3a, zinc (II) complex (4a), copper (II) complex (4b), cobalt (II) complex (4c) and cadmium (II) complex (4d).
Molecules 25 02946 g001
Figure 2. 1H-NMR spectra for sulfonamide ligand (3a) and its complexes (4ad). At the bottom part of the image is represented a detail of aromatic zone (7–11 ppm).
Figure 2. 1H-NMR spectra for sulfonamide ligand (3a) and its complexes (4ad). At the bottom part of the image is represented a detail of aromatic zone (7–11 ppm).
Molecules 25 02946 g002
Figure 3. 13C{1H}-NMR spectra detail (110–160 ppm) for sulfonamide ligand (3a), Zn (II) and Cd (II) complexes.
Figure 3. 13C{1H}-NMR spectra detail (110–160 ppm) for sulfonamide ligand (3a), Zn (II) and Cd (II) complexes.
Molecules 25 02946 g003
Figure 4. (A) Molecular structure of [Co(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] 4c complex. (B) Molecular structure of [Cu(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] 4b complex.
Figure 4. (A) Molecular structure of [Co(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] 4c complex. (B) Molecular structure of [Cu(N-(quinoline-8-yl)-4-chloro-benzenesulfonamide)2] 4b complex.
Molecules 25 02946 g004
Figure 5. (A) The antibacterial activity for QBSC compounds 4a (CD 75Zn), 4b (CD 75Cu), 4c (CD 75Co) and 4d (CD 75Cd) against S. aureus (C+: positive control; C−: negative control). (B) The antibacterial activity for QBSC compounds 4a (CD 75Zn), 4b (CD 75Cu), 4c (CD 75Co) and 4d (CD 75Cd) against E. coli (C+: positive control; C−: negative control). (C) The antifungal activity for QBSC compounds 4a (CD 75Zn), 4b (CD 75Cu), 4c (CD 75Co) and 4d (CD 75Cd) against C. albicans (C+: positive control; C−: negative control).
Figure 5. (A) The antibacterial activity for QBSC compounds 4a (CD 75Zn), 4b (CD 75Cu), 4c (CD 75Co) and 4d (CD 75Cd) against S. aureus (C+: positive control; C−: negative control). (B) The antibacterial activity for QBSC compounds 4a (CD 75Zn), 4b (CD 75Cu), 4c (CD 75Co) and 4d (CD 75Cd) against E. coli (C+: positive control; C−: negative control). (C) The antifungal activity for QBSC compounds 4a (CD 75Zn), 4b (CD 75Cu), 4c (CD 75Co) and 4d (CD 75Cd) against C. albicans (C+: positive control; C−: negative control).
Molecules 25 02946 g005
Table 1. Representative bands of sulfonamide ligand 3a and its complexes with divalent ions Zn2+, Cu2+, Co2+ and Cd2+.
Table 1. Representative bands of sulfonamide ligand 3a and its complexes with divalent ions Zn2+, Cu2+, Co2+ and Cd2+.
ν (cm−1)Sulfonamide Ligand (3a)Zinc Complex (4a)Copper Complex (4b)Cobalt Complex (4c)Cadmium Complex (4d)
νN-H3267 (m)----
νasSO21372 (s-m)1389 (s-m)1385 (s-m)1386 (s-m)1392 (s-m)
νsymSO21177 (s)1138 (s)1155 (s)1151 (s)1136 (s)
νC-N1584 (m)1583 (m)1583 (m)1584 (m)1578 (m)
νS-N927 (m)954 (m)954 (m)961 (m)957 (m)
νC-S624 (s)624 (s)629 (s)624 (s)621 (s)
ν—stretching; s—strong; m—medium; w—weak; as—asymmetric; sym—symmetric.
Table 2. The antibacterial and antifungal activity for ligand 3a and QBSC 4ad compounds.
Table 2. The antibacterial and antifungal activity for ligand 3a and QBSC 4ad compounds.
Strain Diameter of Inhibition Zone
a 3aa 4a (Zn)a 4b (Cu)a 4c (Co)a 4d (Cd)
S. aureus ATCC 2592318 ± 1.7311 ± 1.7316 ± 117 ± 221± 2
E. coli ATCC 25922012 ± 214.5 ± 210.7 ± 219 ± 1.73
C. albicans ATCC 1023126.5± 1.8012 ± 2011 ± 125± 1.15
All values represented in the table are average of results of five separately conducted experiments. Underline means active and bold and underline means very active. a Diameter of inhibition zone (mm), a X ± SD, mean of five measurements ± standard deviation.
Table 3. The minimum inhibitory concentration (MIC) for ligand 3a and QBSC 4ad compounds (mg/mL).
Table 3. The minimum inhibitory concentration (MIC) for ligand 3a and QBSC 4ad compounds (mg/mL).
StrainMIC (mg/mL)
3a4a (Zn)4b (Cu)4c (Co)4d (Cd)
S. aureus ATCC 2592312.5250.0487512.50.00019
E. coli ATCC 25922-250.0487512.50.00609
C. albicans ATCC 1023112.512.5-12.50.00019

Share and Cite

MDPI and ACS Style

Diaconu, D.; Mangalagiu, V.; Amariucai-Mantu, D.; Antoci, V.; Giuroiu, C.L.; Mangalagiu, I.I. Hybrid Quinoline-Sulfonamide Complexes (M2+) Derivatives with Antimicrobial Activity. Molecules 2020, 25, 2946. https://doi.org/10.3390/molecules25122946

AMA Style

Diaconu D, Mangalagiu V, Amariucai-Mantu D, Antoci V, Giuroiu CL, Mangalagiu II. Hybrid Quinoline-Sulfonamide Complexes (M2+) Derivatives with Antimicrobial Activity. Molecules. 2020; 25(12):2946. https://doi.org/10.3390/molecules25122946

Chicago/Turabian Style

Diaconu, Dumitrela, Violeta Mangalagiu, Dorina Amariucai-Mantu, Vasilichia Antoci, Cristian Levente Giuroiu, and Ionel I. Mangalagiu. 2020. "Hybrid Quinoline-Sulfonamide Complexes (M2+) Derivatives with Antimicrobial Activity" Molecules 25, no. 12: 2946. https://doi.org/10.3390/molecules25122946

Article Metrics

Back to TopTop